Abstract
The recent availability of molecular targeted therapies leads to a reconsideration of the treatment strategy for patients with distant metastases from medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered.
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Medullary / drug therapy*
-
Carcinoma, Medullary / pathology
-
Carcinoma, Neuroendocrine
-
Clinical Trials as Topic / standards
-
Humans
-
Molecular Targeted Therapy
-
Patient Selection
-
Piperidines / adverse effects
-
Piperidines / therapeutic use*
-
Protein Kinase Inhibitors / therapeutic use*
-
Quinazolines / adverse effects
-
Quinazolines / therapeutic use*
-
Thyroid Neoplasms / drug therapy*
-
Thyroid Neoplasms / secondary
Substances
-
Antineoplastic Agents
-
Piperidines
-
Protein Kinase Inhibitors
-
Quinazolines
-
vandetanib
Supplementary concepts
-
Thyroid cancer, medullary